The short answer
Survodutide and mazdutide are GLP-1/glucagon dual agonists. Adding glucagon-receptor activity increases energy expenditure and mobilises hepatic fat, which is why both have been studied in metabolic liver disease alongside obesity. Mazdutide is approved in China; survodutide remains investigational with Phase 3 data reported.
Key facts
- Survodutide
- BI 456906 (Boehringer Ingelheim / Zealand Pharma)
- Mazdutide
- IBI362 (Innovent / Eli Lilly)
- Class
- GLP-1 / glucagon dual receptor agonists
- Mazdutide status
- Approved in China; not US or EU
- Mazdutide Phase 3
- ~20% reduction on 9 mg
- Additional target
- Hepatic fat / metabolic liver disease
Why adding glucagon seems backwards
Glucagon raises blood glucose, so deliberately activating its receptor in people with metabolic disease looks like the wrong direction. The resolution is that glucagon does more than mobilise glucose: it increases resting energy expenditure and drives hepatic lipid oxidation. When paired with sufficient GLP-1 agonism, the glucose-raising effect is offset while the energy-expenditure and liver-fat effects remain. The balance between the two activities is the central design problem.
Survodutide
Survodutide, developed by Boehringer Ingelheim with Zealand Pharma under the code BI 456906, is a GLP-1/glucagon dual agonist. Its Phase 2 programme reported reductions in liver fat that positioned it as a candidate in metabolic dysfunction-associated steatohepatitis as well as obesity, and it has progressed into Phase 3 including a cardiovascular outcomes study and a Japanese programme registered as SYNCHRONIZE-JP.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Mazdutide
Mazdutide, developed by Innovent Biologics in collaboration with Eli Lilly under the code IBI362, is a GLP-1/glucagon dual agonist derived from oxyntomodulin. Phase 3 work in Chinese adults with obesity reported approximately 20% weight reduction on the 9 mg dose. It has been approved in China but holds no authorisation in the United States or European Union, and further trials continue across obstructive sleep apnoea and type 2 diabetes remission.
Where the glucagon arm may matter most
The distinguishing claim for this class is not weight reduction alone, since retatrutide and CagriSema report larger figures. It is the direct effect on hepatic fat. Metabolic liver disease is a large and poorly served indication, and a compound that addresses liver fat and body weight together has a different clinical case from one that addresses weight alone.
How this relates to retatrutide
Retatrutide contains glucagon-receptor agonism as one of its three activities, so it shares this mechanism rather than competing with it. The difference is that retatrutide adds GIP on top, making it a triple rather than dual agonist. Studying the duals in isolation is part of how the field works out how much each receptor contributes.
Frequently asked questions
Does glucagon agonism raise blood sugar?
On its own it would. In these compounds the GLP-1 component offsets it, and the balance between the two activities is a deliberate design parameter.
Is mazdutide available outside China?
No. It holds Chinese approval but no US or EU authorisation.
What is oxyntomodulin?
A naturally occurring gut peptide that activates both GLP-1 and glucagon receptors. It is the biological precedent this drug class is built on.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- TrialClinicalTrials.gov: survodutide cardiovascular outcomes (NCT06077864)clinicaltrials.gov
- TrialClinicalTrials.gov: SYNCHRONIZE-JP (NCT06176365)clinicaltrials.gov
- RefBeyond GLP-1s: which weight-loss drugs are on the way. Medscapemedscape.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What the Data Says About Weight Regain After StoppingSTEP-1 extension found about two-thirds of lost weight returned within a year of stopping semaglutide. Meta-analyses put regain at roughly 0.8 kg per month.
- How to Read a Weight-Loss Trial Result ProperlyEstimands, populations, durations and discontinuation rates. Why CagriSema reports both 22.7% and 20.4%, and why headline percentages are not comparable.
- Oral Semaglutide vs OrforglipronBoth are tablets, only one is a peptide. Why oral semaglutide needs SNAC and a fasting window while orforglipron needs neither, and what that costs each.
- What Is Aleniglipron? The Second Oral Small-Molecule GLP-1Aleniglipron is an oral non-peptide GLP-1 agonist from Structure Therapeutics. ACCESS reported 12.1% at 36 weeks; ACCESS II reported 15.3% absolute at 44 weeks.
- What Is Semaglutide? Structure, Mechanism and EvidenceSemaglutide is a GLP-1 analogue with 94% homology to native GLP-1. Its structure, the C18 diacid that gives it a weekly half-life, and the SELECT outcome data.